Developer docs
API playgroundTry for free, no card

Search company profiles

STERO Biotech

Full company profile

uuid000vm8l

Namestring
STERO Biotech
Legal namestring
STERO Biotechs Ltd.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

STERO Biotechs Ltd. is a privately held, clinical-stage biopharmaceutical company founded in 2017 and headquartered in Bnei Brak, Israel. The company is developing a single proprietary drug candidate, ST-101, based on Cannabidiol (CBD) — a non-psychotropic component of Cannabis sativa with immunomodulatory and anti-inflammatory properties. ST-101 is positioned as a steroid-sparing adjunct, intended to either enhance the therapeutic effect of corticosteroids, reduce the steroid dose required, or mitigate steroid-related side effects in patients with autoimmune and inflammatory diseases.

The company's pipeline is anchored by a foundational Phase 2 clinical trial in Graft Versus Host Disease (GVHD) that demonstrated CBD significantly reduces steroid requirements while arresting or curing disease. On that basis, STERO has expanded into multi-center Phase 2a trials in steroid-dependent Crohn's disease (initiated Q1 2020), chronic urticaria (Q3 2020), and severe COVID-19 (Phase 1/2 completed Q1 2021). The company holds a granted US patent (August 2018) covering CBD-based steroid-sparing therapy across over 130 autoimmune and inflammatory diseases.

STERO generates no commercial revenue and operates with 1-10 employees. Its business model will eventually rely on pharmaceutical product sales or licensing of ST-101 upon regulatory approval. The company is strategically partnered with Mor Research Applications, the technology transfer arm of CLALIT Health Services — Israel's largest HMO with 4.5M+ members, 14 hospitals, and 2,000+ clinics — providing access to clinical infrastructure, key opinion leaders, and patient populations for trials and future Israeli commercialization. The company is also a member of the Cannabis Innovation Center (CIC) consortium. No disclosed funding rounds exist, and the company appears to operate on founder capital and partnership support.

Short descriptiontext

STERO Biotechs Ltd. is a clinical-stage Israeli biopharmaceutical company developing ST-101, a CBD-based steroid-sparing therapy for autoimmune and inflammatory diseases including Crohn's disease, chronic urticaria, GVHD, and severe COVID-19, partnered with Mor Research Applications and CLALIT Health Services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabinoid therapeutics, steroid sparing drugs, inflammatory disease treatments, clinical stage biopharmaceuticals, autoimmune disease therapies
Industry1 code
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cannabinoid Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

STERO Biotech is a clinical-stage company. The company is developing ST-101, a CBD-based product targeted for steroid sparing in multiple indications. Revenue model will be through pharmaceutical product sales upon regulatory approval. Currently conducting clinical trials in Crohn's disease, chronic urticaria, and severe COVID-19.

sterobiotechs.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

STERO Biotech is a clinical-stage biopharmaceutical company developing ST-101, a Cannabidiol (CBD)-based drug candidate designed for steroid-sparing applications across multiple inflammatory and autoimmune disease indications. The product leverages CBD's immunomodulatory and anti-inflammatory properties to either enhance the therapeutic effect of steroids or reduce required steroid dosage while maintaining treatment efficacy. The company is currently advancing ST-101 through Phase IIa clinical trials in steroid-dependent Crohn's disease and chronic urticaria, and has completed a Phase I/II trial in severe COVID-19.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • CBD administration enhanced therapeutic effect of steroids or reduced steroid dosage while maintaining or improving original therapeutic effect in GVHD trial
+3 more records
Product overview1 text field

STERO Biotech is a clinical-stage biopharmaceutical company developing a single proprietary CBD-based drug product, ST-101, designed for steroid-sparing applications across multiple inflammatory and autoimmune diseases. The product is undergoing Phase IIa clinical trials in steroid-dependent Crohn's disease, chronic urticaria, and severe COVID-19. The company's treatment approach uses Cannabidiol (CBD), a non-psychotropic component of Cannabis sativa, to either enhance the therapeutic effect of steroids, reduce steroid dosage requirements, or reduce steroid-associated side effects in patients.

Product and service1 record
1ST-101
CategoryCannabinoid Pharmaceutical
Description

ST-101 is a CBD-based drug candidate targeted for steroid sparing in multiple inflammatory and autoimmune disease indications. It leverages the immunomodulatory and anti-inflammatory properties of Cannabidiol (CBD) to either enhance steroid therapeutic effects or reduce required steroid dosage while maintaining treatment efficacy. Currently undergoing Phase IIa clinical trials in steroid-dependent Crohn's disease, chronic urticaria, and severe COVID-19.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Mor Research Applications Ltd
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Mor Research Applications is the technology transfer arm of CLALIT Health Services, established in 1994. The company has handled over 300 patent applications and established over 50 portfolio start-up companies in pharmaceuticals, medical devices, diagnostics, and digital health. This strategic partnership provides STERO with proximity to Israel's leading research and clinical centers, direct access to collaboration with leading KOLs and physicians, and insider access to Israel's innovation and IP generation centers. STERO was established in partnership with Mor Research Applications in 2017.

sterobiotechs.com
2CLALIT Health Services
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CLALIT Health Services is the largest HMO in Israel with over 4.5M members, operating over 2,000 community clinics and 14 full-scale hospitals. CHS has 32,000 employees including over 9,000 physicians. This partnership provides STERO direct access to clinical infrastructure, patient populations for trials, and medical expertise across all fields of medicine.

sterobiotechs.com
3The Cannabis Innovation Center (CIC)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

STERO is a member of the Cannabis Innovation Center (CIC), a group of IP-protected startup companies in the biotech space with emphasis on Cannabis development. CIC includes companies such as Stero Biotechs, CannaLean Biotechs, CannaMore Biotechs and others, providing a competitive advantage in pharma and drug development areas.

sterobiotechs.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global cannabis company with a dedicated pharmaceutical and cannabinoid drug development arm. Comparable as a well-capitalized incumbent in the cannabis-pharma convergence space.

TypeDirect peer
Description

Pioneer in CBD-based prescription drugs (Epidiolex for rare epilepsies); acquired by Jazz Pharmaceuticals in 2021. Most directly comparable as a cannabinoid-derived pharmaceutical developer that took a CBD asset through FDA approval and global commercialization.

TypeEmerging player
Description

Clinical-stage cannabinoid-derived pharmaceutical developer for inflammatory and CNS indications. Comparable in stage, therapeutic approach (cannabinoid chemistry), and indication strategy to STERO.

4Kalytera Therapeutics
TypeDirect peer
Description

Acquired the original CBD-for-GVHD IP from STERO's founders (Moshe Yeshurun et al.). Directly comparable as a clinical-stage cannabinoid pharmaceutical company pursuing steroid-sparing and anti-inflammatory indications, sharing scientific lineage with STERO.

5Mor Research Applications
TypeOthers
Description

Technology transfer arm of CLALIT Health Services and STERO's founding strategic partner. Comparable as a key ecosystem enabler and pipeline generator for Israeli biotech, including the formation of STERO itself.

TypeDirect peer
Description

Clinical-stage developer of cannabinoid-derived therapeutics (Lenabasum) targeting autoimmune and inflammatory diseases including systemic sclerosis and dermatomyositis. Closely comparable business model, mechanism, and indication strategy to STERO.

TypeEmerging player
Description

Clinical-stage immunology company with a focus on severe COVID-19 and inflammatory indications. Comparable as a small-cap clinical-stage biopharma targeting steroid-dependent inflammatory disease states, overlapping with STERO's COVID and autoimmune programs.

8CannaMore Biotechs
TypeEmerging player
Description

Israeli cannabis biotech startup within the same Cannabis Innovation Center (CIC) ecosystem as STERO, with shared operational leadership (COO Guy Defrin). Comparable as a regional, early-stage cannabis-pharma peer with shared infrastructure and talent.

9Tetra Bio-Pharma
TypeEmerging player
Description

Canadian clinical-stage cannabinoid pharmaceutical company developing cannabinoid-derived prescription drugs for inflammatory and pain indications. Comparable as a small-cap, clinical-stage cannabinoid pharma pursuing regulated drug pathways.

10Tilray Brands
TypeBroad incumbent
Description

Large cannabis company with a pharmaceutical division developing cannabinoid-based prescription products. Comparable as a broader incumbent in cannabis-derived pharma with significantly greater capital and commercial infrastructure than STERO.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

STERO Biotech

Cannabinoid Biopharmaceuticalssterobiotechs.com

STERO Biotechs Ltd. is a clinical-stage Israeli biopharmaceutical company developing ST-101, a CBD-based steroid-sparing therapy for autoimmune and inflammatory diseases including Crohn's disease, chronic urticaria, GVHD, and severe COVID-19, partnered with Mor Research Applications and CLALIT Health Services.

What STERO Biotech does

STERO Biotechs Ltd. is a privately held, clinical-stage biopharmaceutical company founded in 2017 and headquartered in Bnei Brak, Israel. The company is developing a single proprietary drug candidate, ST-101, based on Cannabidiol (CBD) — a non-psychotropic component of Cannabis sativa with immunomodulatory and anti-inflammatory properties. ST-101 is positioned as a steroid-sparing adjunct, intended to either enhance the therapeutic effect of corticosteroids, reduce the steroid dose required, or mitigate steroid-related side effects in patients with autoimmune and inflammatory diseases.

The company's pipeline is anchored by a foundational Phase 2 clinical trial in Graft Versus Host Disease (GVHD) that demonstrated CBD significantly reduces steroid requirements while arresting or curing disease. On that basis, STERO has expanded into multi-center Phase 2a trials in steroid-dependent Crohn's disease (initiated Q1 2020), chronic urticaria (Q3 2020), and severe COVID-19 (Phase 1/2 completed Q1 2021). The company holds a granted US patent (August 2018) covering CBD-based steroid-sparing therapy across over 130 autoimmune and inflammatory diseases.

STERO generates no commercial revenue and operates with 1-10 employees. Its business model will eventually rely on pharmaceutical product sales or licensing of ST-101 upon regulatory approval. The company is strategically partnered with Mor Research Applications, the technology transfer arm of CLALIT Health Services — Israel's largest HMO with 4.5M+ members, 14 hospitals, and 2,000+ clinics — providing access to clinical infrastructure, key opinion leaders, and patient populations for trials and future Israeli commercialization. The company is also a member of the Cannabis Innovation Center (CIC) consortium. No disclosed funding rounds exist, and the company appears to operate on founder capital and partnership support.

STERO Biotech firmographics

Firmographics
Name
STERO Biotech
Legal name
STERO Biotechs Ltd.
Website
https://sterobiotechs.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
STERO Biotechs Ltd. is a clinical-stage Israeli biopharmaceutical company developing ST-101, a CBD-based steroid-sparing therapy for autoimmune and inflammatory diseases including Crohn's disease, chronic urticaria, GVHD, and severe COVID-19, partnered with Mor Research Applications and CLALIT Health Services.
Ownership category
akta.pro rank

STERO Biotech industry classification

Industry
Product category
Cannabinoid Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Cannabinoid therapeutics
  • Steroid sparing drugs
  • Inflammatory disease treatments
  • Clinical stage biopharmaceuticals
  • Autoimmune disease therapies

Where STERO Biotech is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

STERO Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: STERO Biotech is a clinical-stage company. The company is developing ST-101, a CBD-based product targeted for steroid sparing in multiple indications. Revenue model will be through pharmaceutical product sales upon regulatory approval. Currently conducting clinical trials in Crohn's disease, chronic urticaria, and severe COVID-19.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

STERO Biotech product offering

Product offering

Core offering

STERO Biotech is a clinical-stage biopharmaceutical company developing ST-101, a Cannabidiol (CBD)-based drug candidate designed for steroid-sparing applications across multiple inflammatory and autoimmune disease indications. The product leverages CBD's immunomodulatory and anti-inflammatory properties to either enhance the therapeutic effect of steroids or reduce required steroid dosage while maintaining treatment efficacy. The company is currently advancing ST-101 through Phase IIa clinical trials in steroid-dependent Crohn's disease and chronic urticaria, and has completed a Phase I/II trial in severe COVID-19.

Product overview

STERO Biotech is a clinical-stage biopharmaceutical company developing a single proprietary CBD-based drug product, ST-101, designed for steroid-sparing applications across multiple inflammatory and autoimmune diseases. The product is undergoing Phase IIa clinical trials in steroid-dependent Crohn's disease, chronic urticaria, and severe COVID-19. The company's treatment approach uses Cannabidiol (CBD), a non-psychotropic component of Cannabis sativa, to either enhance the therapeutic effect of steroids, reduce steroid dosage requirements, or reduce steroid-associated side effects in patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • ST-101 ST-101 is a CBD-based drug candidate targeted for steroid sparing in multiple inflammatory and autoimmune disease indications. It leverages the immunomodulatory and anti-inflammatory properties of Cannabidiol (CBD) to either enhance steroid therapeutic effects or reduce required steroid dosage while maintaining treatment efficacy. Currently undergoing Phase IIa clinical trials in steroid-dependent Crohn's disease, chronic urticaria, and severe COVID-19.

Quantifiable outcome

  • CBD administration enhanced therapeutic effect of steroids or reduced steroid dosage while maintaining or improving original therapeutic effect in GVHD trial
  • +3 more outcomes

Companies that use STERO Biotech

Customer profile

Segments5 records

Ideal customer profiles2 records

STERO Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

STERO Biotech partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Mor Research Applications LtdcoreStrategic or Co-development Partner · 1 January 2017Mor Research Applications is the technology transfer arm of CLALIT Health Services, established in 1994. The company has handled over 300 patent applications and established over 50 portfolio start-up companies in pharmaceuticals, medical devices, diagnostics, and digital health. This strategic partnership provides STERO with proximity to Israel's leading research and clinical centers, direct access to collaboration with leading KOLs and physicians, and insider access to Israel's innovation and IP generation centers. STERO was established in partnership with Mor Research Applications in 2017.
  • CLALIT Health ServicescoreStrategic or Co-development PartnerCLALIT Health Services is the largest HMO in Israel with over 4.5M members, operating over 2,000 community clinics and 14 full-scale hospitals. CHS has 32,000 employees including over 9,000 physicians. This partnership provides STERO direct access to clinical infrastructure, patient populations for trials, and medical expertise across all fields of medicine.
  • The Cannabis Innovation Center (CIC)minorStrategic or Co-development PartnerSTERO is a member of the Cannabis Innovation Center (CIC), a group of IP-protected startup companies in the biotech space with emphasis on Cannabis development. CIC includes companies such as Stero Biotechs, CannaLean Biotechs, CannaMore Biotechs and others, providing a competitive advantage in pharma and drug development areas.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

STERO Biotech competitors and assessment

Company assessment

Broad incumbents

  • Canopy Growth Corporation: Global cannabis company with a dedicated pharmaceutical and cannabinoid drug development arm. Comparable as a well-capitalized incumbent in the cannabis-pharma convergence space.
  • Tilray Brands: Large cannabis company with a pharmaceutical division developing cannabinoid-based prescription products. Comparable as a broader incumbent in cannabis-derived pharma with significantly greater capital and commercial infrastructure than STERO.

Direct peers

  • GW Pharmaceuticals (Jazz Pharmaceuticals): Pioneer in CBD-based prescription drugs (Epidiolex for rare epilepsies); acquired by Jazz Pharmaceuticals in 2021. Most directly comparable as a cannabinoid-derived pharmaceutical developer that took a CBD asset through FDA approval and global commercialization.
  • Kalytera Therapeutics: Acquired the original CBD-for-GVHD IP from STERO's founders (Moshe Yeshurun et al.). Directly comparable as a clinical-stage cannabinoid pharmaceutical company pursuing steroid-sparing and anti-inflammatory indications, sharing scientific lineage with STERO.
  • Corbus Pharmaceuticals: Clinical-stage developer of cannabinoid-derived therapeutics (Lenabasum) targeting autoimmune and inflammatory diseases including systemic sclerosis and dermatomyositis. Closely comparable business model, mechanism, and indication strategy to STERO.

Emerging players

  • Emerald Health Pharmaceuticals: Clinical-stage cannabinoid-derived pharmaceutical developer for inflammatory and CNS indications. Comparable in stage, therapeutic approach (cannabinoid chemistry), and indication strategy to STERO.
  • AIM ImmunoTech: Clinical-stage immunology company with a focus on severe COVID-19 and inflammatory indications. Comparable as a small-cap clinical-stage biopharma targeting steroid-dependent inflammatory disease states, overlapping with STERO's COVID and autoimmune programs.
  • CannaMore Biotechs: Israeli cannabis biotech startup within the same Cannabis Innovation Center (CIC) ecosystem as STERO, with shared operational leadership (COO Guy Defrin). Comparable as a regional, early-stage cannabis-pharma peer with shared infrastructure and talent.
  • Tetra Bio-Pharma: Canadian clinical-stage cannabinoid pharmaceutical company developing cannabinoid-derived prescription drugs for inflammatory and pain indications. Comparable as a small-cap, clinical-stage cannabinoid pharma pursuing regulated drug pathways.

Others

  • Mor Research Applications: Technology transfer arm of CLALIT Health Services and STERO's founding strategic partner. Comparable as a key ecosystem enabler and pipeline generator for Israeli biotech, including the formation of STERO itself.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

STERO Biotech social profiles

Digital presence

STERO Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

STERO Biotech leadership team

Management profile

Number of profiles

Profiles7 records

STERO Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

STERO Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STERO Biotech

What does STERO Biotech do?

STERO Biotech is a clinical-stage biopharmaceutical company developing ST-101, a Cannabidiol (CBD)-based drug candidate designed for steroid-sparing applications across multiple inflammatory and autoimmune disease indications. The product leverages CBD's immunomodulatory and anti-inflammatory properties to either enhance the therapeutic effect of steroids or reduce required steroid dosage while maintaining treatment efficacy. The company is currently advancing ST-101 through Phase IIa clinical trials in steroid-dependent Crohn's disease and chronic urticaria, and has completed a Phase I/II trial in severe COVID-19.

Is STERO Biotech a public or private company?

STERO Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was STERO Biotech founded?

STERO Biotech was founded in 2017. It employs 1 to 10 people.

Where is STERO Biotech based?

STERO Biotech is headquartered in Tel Aviv, Israel, in the Middle East region.

How does STERO Biotech make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are STERO Biotech's main competitors?

Broad incumbents on record are Canopy Growth Corporation and Tilray Brands. Direct peers are GW Pharmaceuticals (Jazz Pharmaceuticals), Kalytera Therapeutics and Corbus Pharmaceuticals. Emerging players are Emerald Health Pharmaceuticals, AIM ImmunoTech, CannaMore Biotechs and Tetra Bio-Pharma. Mor Research Applications is listed as an others.

Does STERO Biotech have an API?

No public API is recorded for STERO Biotech.

What industry is STERO Biotech in?

STERO Biotech's product category is Cannabinoid Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireStero Biotechs report initial results in the Exploratory Study it supports of CBD-based treatment for Covid-19 severe patientsStero Biotechs, an Israel-based clinical-stage company, has reported encouraging preliminary results from a pilot clinical trial testing CBD-based treatment for severe and critical COVID-19 patients at Rabin Medical Center. The trial, which has recruited 11 of a planned 20 patients, showed that CBD has beneficial effects on inflammatory markers elevated in COVID-19 patients, though investigators note the sample size is insufficient for conclusive evidence and results warrant a randomized controlled study. The ongoing study, approved by the Helsinki Committee, aims to explore CBD's efficacy in reducing inflammatory processes that harm patients with severe acute respiratory distress syndrome.PR NewswireStero Biotechs supports an Exploratory Study of CBD-based treatment for COVID-19 severe patientsStero Biotechs, an Israel-based clinical-stage company, is supplying and supporting an investigator-initiated clinical trial for a CBD-based treatment targeting severe and critical COVID-19 patients with respiratory failure from acute respiratory distress syndrome (ARDS) at Rabin Medical Center in Israel. The Proof of Concept study, conducted in cooperation with Mor Research Applications (the technology transfer office of Clalit HMO), has received Helsinki Committee approval and plans to treat 20 patients over a 14-28 day cycle, with a pending expansion to a Phase 2a multi-center trial involving 40 additional patients under FDA clinical trial guidelines. The company aims to enhance the therapeutic effect of steroid treatments and reduce mortality caused by cytokine storm.PR NewswireStero Biotechs Announce an IP Protected Clinical Trial for COVID-19 Patients Using a CBD-Steroid TreatmentStero Biotechs, in collaboration with Mor Research Applications and Clalit Health Services, announced a new clinical trial to test a CBD-steroid treatment for hospitalized COVID-19 patients at Rabin Medical Center in Israel. The initial phase aims to evaluate safety and efficacy in 10 patients, with plans to scale up to a larger multi-center study if successful under FDA guidelines.GlobeNewswireKalytera Provides Additional Detail Regarding Terms of Stero Biotechs, Ltd. AcquisitionKalytera announced its planned acquisition of Stero Biotechs for $30 million, to be paid in shares. The deal includes $15 million at closing and $10 million upon completion of Phase 2a studies, with a 266% premium over the last share price. The acquisition is subject to regulatory and shareholder approvals.GlobeNewswireKalytera Announces Trading HaltKalytera Therapeutics placed its securities in a trading halt pending review by the TSX Venture Exchange of documents for its planned acquisition of Stero Biotechs, Ltd. The halt was announced on March 5, 2020, with no further details provided.GlobeNewswireKalytera to Acquire Stero Biotechs, Ltd.Kalytera signed a letter of intent to acquire Stero Biotechs for $30 million, with $15 million in shares at closing and $10 million upon completion of Phase 2a studies. The deal adds Stero's CBD steroid-sparing programs covering over 130 diseases, with closing expected around May 1, 2020.PR NewswireStero Biotechs to Commence Phase 2a Clinical Trial of Cannabidiol-Based Formulation for Patients With Crohn's DiseaseStero Biotechs received Helsinki approval to commence a Phase 2a clinical trial for ST-SDCD-01, a cannabidiol-based formulation designed as a steroid-sparing therapy for patients with Steroid Dependent Crohn's Disease. The randomized, double-blind study will involve up to 30 participants across four Israeli medical facilities and is scheduled to begin in July 2019. This development follows an active partnership with CLALIT HEALTH SERVICES, which provides access to patient data and clinical infrastructure.PR NewswireStero Biotechs to Commence Phase 2 Clinical Trial of ST-AH-01 Cannabidiol Formulation for Ground Breaking Maintenance Therapy and Steroid Reduction in Patients With Autoimmune HepatitisStero Biotechs has received Ethics Committee approval from Israel's Ministry of Health to commence a Phase 2 clinical trial of its ST-AH-01 Cannabidiol formulation in 15 patients with autoimmune hepatitis at Rabin Medical Center near Tel Aviv.PR NewswireSTERO Biotechs Secures Patent of CBD as Steroid Sparing Treatment, Breakthrough Will Potentially Allow Significant Dosage ReductionSTERO Biotechs Ltd., an Israeli clinical-stage company, has received a notice of allowance for a U.S. patent covering CBD-based steroid sparing treatment for over 100 autoimmune and chronic inflammatory diseases, scheduled for official grant in October 2018. The treatment aims to minimize the adverse effects of steroids, which are widely used but cause conditions including hypertension, osteoporosis, and type 2 diabetes, by allowing physicians to prescribe lower steroid doses while retaining therapeutic efficacy. The company plans to commence clinical trials in Q4 2018, having established a partnership with CLALIT Health SERVICES—the largest HMO in Israel—to access its network of 14 hospitals, over 2,000 clinics, and 4.5 million members for research.